We are live on ! Find out more
NEPH icon

Nephros
NEPH

17 hedge funds and large institutions have $1.14M invested in Nephros in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

6% more funds holding

Funds holding: 16 → 17 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.43% less ownership

Funds ownership: 41.98% → 41.55% (-0.43%)

66% less capital invested

Capital invested by funds: $3.36M → $1.14M (-$2.22M)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
7
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BA
Bard Associates
Illinois
+$46.8K
2
State Street
State Street
Massachusetts
+$42.4K
3
Citadel Advisors
Citadel Advisors
Florida
+$32.7K
4
Morgan Stanley
Morgan Stanley
New York
+$29K
5
EP
Elkhorn Partners
Nebraska
+$27.8K

Top Sellers

Rank Fund Capital Flow
1
CPA
Cowen Prime Advisors
New York
-$102K
2
Renaissance Technologies
Renaissance Technologies
New York
-$89K
3
CF
Cantor Fitzgerald
New York
-$56K
4
BlackRock
BlackRock
New York
-$36.8K
5
WC
Wexford Capital
Florida
-$23.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
1
Bard Associates
Illinois
$404K +$46.8K +17,346 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$188K -$810 -300 -0.2%
WC
3
Wexford Capital
Florida
$175K -$23.9K -8,858 -0.2%
HighTower Advisors
4
HighTower Advisors
Illinois
$85K – – –
CPA
5
Cowen Prime Advisors
New York
$65K -$102K -37,900 -47%
William Blair & Company
6
William Blair & Company
Illinois
$55K – – –
EP
7
Elkhorn Partners
Nebraska
$52K +$27.8K +10,288 +43%
Morgan Stanley
8
Morgan Stanley
New York
$28K +$29K +10,729 +143%
State Street
9
State Street
Massachusetts
$24K +$42.4K +15,698 New
Citadel Advisors
10
Citadel Advisors
Florida
$19K +$32.7K +12,123 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$17K +$3.15K +1,167 +11%
TRCT
12
Tower Research Capital (TRC)
New York
$14K +$23.9K +8,856 +1,977%
Osaic Holdings
13
Osaic Holdings
Arizona
$7K -$11.1K -4,100 -47%
BlackRock
14
BlackRock
New York
$6K -$36.8K -13,619 -77%
TCWM
15
Total Clarity Wealth Management
Illinois
$3K +$4.47K +1,657 New
UBS Group
16
UBS Group
Switzerland
$1K +$1.39K +515 +4,682%
Renaissance Technologies
17
Renaissance Technologies
New York
– -$89K -20,317 Closed
CF
18
Cantor Fitzgerald
New York
– -$56K -12,813 Closed
Wells Fargo
19
Wells Fargo
California
– +$13 +5 +10%

NEPH Hedge Fund Activity: Q2 2022 in Review

17 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Nephros (NEPH) for Q2 2022, worth a combined $1.14M — down 66% from $3.36M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NEPH positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Bard Associates, adding an estimated $46.8K. The largest seller was Cowen Prime Advisors, cutting an estimated $102K.

  • 17 institutional investors held Nephros (NEPH) as of Q2 2022, up from 16 in Q1 2022.
  • Funds reported $1.14M of Nephros stock for Q2 2022, down 66% quarter-over-quarter.
  • 3 funds opened new Nephros positions in Q2 2022 and 2 closed out, a net change of +1 holder.
  • The largest Nephros buyer in Q2 2022 was Bard Associates, an estimated $46.8K added.
  • The largest Nephros seller in Q2 2022 was Cowen Prime Advisors, an estimated $102K sold.

Based on aggregated 13F filings for Q2 2022.